Compare ETB & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Tax-Managed Buy-Write Income Fund Eaton Vance Tax-Managed Buy-Write Income Fund of Beneficial Interest
Current Price
| Metric | ETB | OVID |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 451.8M | 503.9M |
| IPO Year | 2004 | 2017 |
| Metric | ETB | OVID |
|---|---|---|
| Price | $15.07 | $2.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $6.15 |
| AVG Volume (30 Days) | 59.5K | ★ 2.4M |
| Earning Date | 01-01-0001 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $13.86 | $1.21 |
| 52 Week High | $15.82 | $3.11 |
| Indicator | ETB | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 48.03 | 49.33 |
| Support Level | $14.90 | $2.12 |
| Resistance Level | $15.60 | $2.67 |
| Average True Range (ATR) | 0.20 | 0.25 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 68.38 | 41.92 |
Eaton Vance Tax-Managed Buy-Write Income Fund is a United States-based diversified closed ended management investment company. The fund's investment objective is to provide current income and gains, with a secondary objective of capital appreciation. It invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of aerospace and defense, banks, biotechnology, chemicals, consumer finance, industrial conglomerates, and others.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.